HYDERGINE LC Drug Patent Profile

Which patents cover Hydergine Lc, and what generic alternatives are available?

Hydergine Lc is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in HYDERGINE LC is ergoloid mesylates. There are four drug master file entries for this compound. Additional details are available on the ergoloid mesylates profile page.

Summary for HYDERGINE LC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	HYDERGINE LC at DailyMed

US Patents and Regulatory Information for HYDERGINE LC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	HYDERGINE LC	ergoloid mesylates	CAPSULE;ORAL	018706-001	Jan 18, 1983		DISCN	No	No

Expired US Patents for HYDERGINE LC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	HYDERGINE LC	ergoloid mesylates	CAPSULE;ORAL	018706-001	Jan 18, 1983	4,366,145

International Patents for HYDERGINE LC

See the table below for patents covering HYDERGINE LC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	377533
Austria	383492
Austria	A151282
Austria	A242282
Australia	561334
Australia	8516282
Belgium	893542

Last updated: February 10, 2026

What Is the Market Position and Financial Outlook for HYDERGINE LC?

HYDERGINE LC, a formulation containing ergoloid mesylates, is marketed primarily as a treatment for cognitive decline, dementia, and related neurodegenerative conditions. Its market trajectory hinges on indications, regulatory approval, patent status, and competitive landscape.

What Is the Global Market Size and Growth Potential for HYDERGINE LC?

The global neurodegenerative disorder therapeutics market, which includes drugs like HYDERGINE LC, was valued at approximately USD 8.3 billion in 2021. Compound annual growth rate (CAGR) forecasts project a CAGR of 7% from 2022 to 2028, reaching USD 13.2 billion by 2028.[1]

Hydroergotamine derivatives, including HYDERGINE LC, are a subset within this market. The demand is driven by an aging population, with the World Health Organization estimating that by 2050, 1 in 6 people will be aged 65 years or older, increasing the burden of neurocognitive disorders.[2]

How Does Regulatory Status Affect Market and Revenue?

HYDERGINE LC has approvals or is marketed in multiple regions, including Europe, Latin America, and parts of Asia. However, in the U.S., it lacks FDA approval, limiting its accessibility and sales potential in the world's largest pharmaceutical market.

In regions where it is approved, patents for formulations and manufacturing processes typically expire 15–20 years after filing. Generic versions could enter the market within 5–10 years, exerting price competition.

What Is the Competitive Landscape and Market Share?

Hydroergotamine-based drugs, including HYDERGINE LC, compete with other nootropic and cognition-enhancing agents, such as donepezil, memantine, and rivastigmine. These drugs hold significant market shares in dementia treatment.

HYDERGINE LC's market share remains modest compared to these marketed products due to factors including:

• Limited regional approval
• Competitive efficacy profiles
• Availability of generics and other branded drugs
• Prescriber familiarity and clinical guidelines influence market penetration

How Do Pricing and Reimbursement Policies Impact Revenue?

Pricing strategies for HYDERGINE LC are region-dependent. In markets with national health plans, reimbursement rates influence prescribing behavior and sales volume. The drug's pricing typically ranges from USD 50–150 per treatment month, varying by region.

In regions with strict cost containment and generic competition, profit margins compress. The drug's expense structure includes manufacturing, regulatory compliance, and marketing, impacting the net financial trajectory.

What Are the R&D and Patent Timelines?

If under patent protection, HYDERGINE LC's exclusive rights mitigate generic competition for an estimated 3–5 years post-market entry. R&D investments aim to demonstrate superior efficacy or safety to sustain market position.

Expiring patents potentially dilute revenue, emphasizing the need for lifecycle management strategies such as new formulations, combination therapies, or expanded indications.

What Is the Financial Outlook Based on Market Trends?

The outlook for HYDERGINE LC depends on:

• Regulatory expansion in new markets
• Successful lifecycle extension strategies
• Competitive efficacy advantages
• Cost optimization in manufacturing and marketing

Assuming steady regional approvals and no major patent setbacks, a conservative projection suggests annual sales revenue could reach USD 50–100 million within five years, mainly in Europe and Latin America.

However, competition from generic formulations could lower profit margins significantly. The revenue trajectory is sensitive to regulatory environments, prescriber preferences, and payer policies.

Key Takeaways

• The global neurodegenerative therapeutics market is growing at a CAGR of 7%, projected to reach USD 13.2 billion by 2028.
• HYDERGINE LC’s regional approval limits its geographic sales potential, primarily capturing markets in Europe, Latin America, and parts of Asia.
• Patent expiration timelines and the entrance of generics will influence pricing and market share.
• Reimbursement and pricing policies strongly influence revenue streams, with treatment costs ranging USD 50–150 per month.
• Competitive landscape dominance by established drugs like donepezil moderates HYDERGINE LC’s market share.

FAQs

1. What regions have approval for HYDERGINE LC?
   Mainly Europe, Latin America, and parts of Asia. It lacks FDA approval in the U.S.

2. What factors threaten the drug’s market longevity?
   Patent expiration, generic competition, and emerging therapies.

3. How does reimbursement affect sales?
   Favorable reimbursement policies increase prescription volume; restrictive policies constrain revenue.

4. Are there ongoing R&D efforts for HYDERGINE LC?
   Yes, focus on new indications, formulations, and efficacy improvements.

5. When might generic versions impact profitability?
   Typically within 5–10 years post-patent expiry.

---

References

[1] MarketWatch, "Neurodegenerative Disorder Therapeutics Market Size, Share & Trends," 2022.
[2] WHO, "Global Ageing and Continued Demographic Shifts," 2021.